ERBB2 and breast carcinoma: One patient with ERBB2 mutation received no treatment indication for poor clinical performance; one patient with CDK4 mutation was offered treatment with abemaciclib, a CDK4/6 inhibitor indicated for the therapy of patients with breast cancer [36], but did not start the therapy because of the onset of autoimmune thrombocytopenia.